E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
If approved, Zydus Therapeutics plans to launch saroglitazar in the United States in Q4 of FY 27.
imphoenix82
Unlike many existing treatments for fatty liver disease that mainly focus on weight loss, this new experimental drug targets the disease process itself.
imphoenix82
WHO advisory groups recommend prioritizing three candidate therapeutics for Bundibugyo Ebola trials: Mapp Biopharmaceutical’s MBP134, Regeneron’s Maftivimab, and Gilead Sciences’ antiviral remdesivir.
imphoenix82
While medications remain the first-line treatment for trigeminal neuralgia, CyberKnife-based stereotactic radiosurgery can offer significant relief when conventional therapies fail.
imphoenix82
Biohub’s world model brings together open-source AI models — ESMC, ESMFold2, and ESM Atlas — to help researchers better understand proteins and speed up the discovery of new therapeutics.
imphoenix82
The global CAR T-cell therapy market is projected to grow from USD 6.78 billion in 2026 to USD 13.56 billion by 2031.
dineshwori
The purchase of the three vaccine developers could cost Lilly up to USD 3.8 billion.
imphoenix82
The study will initially evaluate the performance of ABILITY’s BCI as a home-use system to restore communication and speech in ALS patients.
imphoenix82
As India targets a USD 130 billion pharmaceutical market by 2030, several key factors are expected to drive its next phase of growth.
dineshwori
Voy India, formerly EarlyFit, will initially focus on weight loss and obesity care before gradually expanding into broader therapeutic areas.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
